STERIS presents a series of webinars that equip medicinal drug product manufacturers and industry stakeholders with information to better manage compliance with the newly released revision of EU GMP Annex 1 in contamination control strategy (CCS) development and documentation.
The presented topics cover a range of process activities, including identification of contamination risks and mitigation strategies critical for compliance with Annex 1. Additionally, the webinars present opportunities for quality and productivity improvement.
Annex 1 FAQs
To comply with Annex 1, pharmaceutical manufacturers are required to identify, review and update critical controls to ensure holistic confidence in the measures implemented for contamination prevention.
STERIS Life Sciences has answered a list of frequently asked questions related to implementation and evaluation of a contamination control strategy for Annex 1 compliance.
